Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Here are latest arrivals approved by the Food and Drug Administration.
Lurbinectedin shrank tumors in a third of people with this less common type of lung cancer.
A Phase II trial reached its primary endpoint of overall response in just over a third of participants.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.